Año 2022 / Volumen 114 / Número 5
Original
Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes

259-265

DOI: 10.17235/reed.2021.7915/2021

Andrea Núñez Ortiz, María Rojas Feria, María Dolores de la Cruz Ramírez, Lourdes Gómez Izquierdo, Claudio Trigo Salado, José Manuel Herrera Justiniano, Eduardo Leo Carnerero,

Resumen
Objective: to evaluate the role of Epstein-Barr virus (EBV) on the intestinal mucosa in the evolution of inflammatory bowel disease (IBD). The risk factors for EBV infection and the frequency of EBV-associated lymphoproliferative disorders in IBD patients were also investigated. Methods: intestinal biopsies of IBD patients with available EBV status determined by Epstein-Barr-encoding RNA (EBER) in situ hybridization were identified in the Pathology Database of our center. Clinical information, including phenotypic characteristics of IBD, previous treatments, diagnosis of lymphoma and patient outcome were reviewed in all cases. Results: fifty-six patients with IBD (28 Crohn’s disease, 27 ulcerative colitis and one unclassified colitis) were included. EBV in intestinal mucosa was positive in 26 patients (46 %) and was associated to a lymphoproliferative syndrome in one case. EBV positivity was associated with severe histological activity (52 % vs 17.2 %; p 0.007), the presence of a lymphoplasmacytic infiltrate (50 % vs 33.3 %; p 0.03) and active steroid treatment (61.5 % vs 33.3 %; p 0.03). Multivariate analyses only found an association between EBV and lymphoplasmacytosis (p 0.001). Escalation in previous treatment was significantly more frequent in the EBER+ group (53.8 % vs 26.7 %; p 0.038). No cases developed lymphoma during follow-up. Conclusions: EBV on the intestinal mucosa is associated with a poor outcome of IBD and the need for escalation of therapy. Lymphoplasmacytic infiltrate is associated with EBV infection. EBER+ patients used steroids more frequently compared with EBER- patients. No EBER+ patients developed lymphoma during follow-up.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
[1] Lidar M, Langevitz P, Barzilai O, et al. Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann N Y Acad Sci. 2009; 1173: 640-48.
[2] Lopes S, Andrade P, Conde S, et al. Looking into enteric virome in patients with IBD: defining guilty or innocence?. Inflamm Bowel Dis 2017; 23: 1278-84.
[3] Ardesia M, Costantino G, Mondello P, et al. Serology of viral infections and tuberculosis screening in an IBD population referred to a tertiary centre of southern Italy. Gastroenterol Res Pract 2017; 2017: 4139656.
[4] Sankaran-Walters S, Ransibrahmanakul K, Grishina I, et al. Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. J Clin Virol 2011; 50: 31-6.
[5] Pezhouh MK, Miller JA, Sharma R, et al. Refractory inflammatory bowel disease: is there a role for Epstein-Barr virus? A case-controlled study using highly sensitive Epstein-Barr virus–encoded small RNA1 in situ hybridization. Hum Pathol 2018; 82: 187–92.
[6] Ciccocioppo R, Racca F, Paolucci S, et al. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement. World J Gastroenterol 2015; 21:1915-26.
[7] Goetgebuer RL, Van der Woude CJ, Ridder L, et al. Clinical and endoscopic complications of Epstein-Barr virus in inflammatory bowel disease: an illustrative case series. Int J Colorectal Dis 2019; 34: 923–26.
[8] Yanai H, Shimizu N, Nagasaki S, et al. Epstein-Barr virus infection of the colon with inflammatory bowel disease. Am J Gastroenterol 1999; 94:1582-86.
[9] Dimitroulia E, Pitiriga VC, Piperaki ET, el al. Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection. Dis Col Rectum 2013; 56: 322-27.
[10] Spieker T, Herbst H. Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. Am J Pathol 2000; 157: 51-57.
[11] Ciccocioppo R, Racca F, Scudeller L, et al. Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease. Immunol Res 2016; 64: 191-203.
[12] Lam GY, Halloran BP, Peters AC, et al. Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: lessons from other inflammatory disorders. World J Gastrointest Pathophysiol 2015, 6: 181-92.
[13] Matsumoto H, Kimura Y, Murao T, et al. Severe colitis associated with both Epstein-Barr Virus and Cytomegalovirus reactivation in a patient with severe aplastic anemia. Case Rep Gastroenterol 2014; 8: 240-44.
[14] Wu S, He C, Tang TY, et al. A review on co-existent Epstein–Barr virus-induced complications in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2019; 31: 1085-91.
[15] Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr virus–positive primary gastrointestinal Hodgkin’s Disease. Association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol, 2000; 24: 66-73.
[16] Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170: 2-6; discussion 16-9.
[17] Shimada T, Nagata N, Okahara K, et al. PCR detection of human herpesviruses in colonic mucosa of individuals with inflammatory bowel disease: comparison with individuals with immunocompetency and HIV infection. PLoS One. 2017 13;12: e0184699.
[18] Nissen LH, Nagtegaal ID, de Jong DJ, et al. Epstein Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders. J Crohns Colitis 2015; 9: 398-403.
[19] Li X, Chen N, You P, et al. The status of Epstein-Barr virus infection in intestinal mucosa of chinese patients with inflammatory bowel disease. Digestion 2019; 99: 126-32.
[20] Hosomi S, Watanabe K, Nishida Y et al. Combined infection of human herpes viruses: a risk factor for subsequent colectomy in ulcerative colitis. Inflamm Bowel Dis 2018; 24: 1307-15.
[21] Lapsia S, Koganti S, Spadaro S et al. Anti-TNFα therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation. J Med Virol 2016; 88: 213-18.
[22] Magro F, Santos- Antunes J, Alburquerque A et al. Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens. Inflamm Bowel Dis 2013; 19:1710-16.
[23] Andreu-Ballester JC, Gil-Borrás R, García-Ballesteros C et al. Epstein-Barr virus is related with 5-aminosalicylic acid, tonsillectomy, and CD19+ cells in Crohn’s disease. World J Gastroenterol 2015;21: 4666-72.
[24] Chang MD, Markham MJ, Liu X. Epstein-Barr virus-positive diffuse large B-cell lymphoma involving the colon in a patient with ulcerative pancolitis and polymiositis on long-term methotrexate therapy. Gastroenterology Res. 2016; 9: 83-86.
Artículos relacionados

Carta

Linfoma T hepatoesplénico y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2023.9472/2023

Carta

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Carta

EBVMCU in a liver-transplant patient

DOI: 10.17235/reed.2021.8064/2021

Revisión

Enfermedad inflamatoria intestinal y trasplante de órganos sólido

DOI: 10.17235/reed.2020.7361/2020

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Caso Clínico

Lesiones serradas en pacientes con enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2019.5910/2018

Editorial

Redes sociales online y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2018.5496/2018

Carta al Editor

Hipertensión portal idiopática por tiopurinas

DOI: 10.17235/reed.2018.5256/2017

Instrucciones para citar
Núñez Ortiz A, Rojas Feria M, de la Cruz Ramírez M, Gómez Izquierdo L, Trigo Salado C, Herrera Justiniano J, et all. Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes. 7915/2021


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1942 veces.
Este artículo ha sido descargado 227 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 21/02/2021

Aceptado: 15/07/2021

Prepublicado: 28/07/2021

Publicado: 06/05/2022

Tiempo de revisión del artículo: 93 días

Tiempo de prepublicación: 157 días

Tiempo de edición del artículo: 439 días


Compartir
Este artículo ha sido valorado por 1 lectores .
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas